{"id":"W2028690273","doi":"10.1002/cncr.25931","title":"A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma","year":2011,"lang":"en","type":"article","venue":"Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Sorafenib; Everolimus; Renal cell carcinoma; Common Terminology Criteria for Adverse Events; Sunitinib; Adverse effect; Rash; Internal medicine; Response Evaluation Criteria in Solid Tumors; Toxicity; Urology; Pharmacology; Oncology; Gastroenterology; Phases of clinical research; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002429221,0.001027805,0.002356255,0.0004301497,0.0004943732,0.0006953789,0.0008880456,0.0007085159,0.002869057],"category_scores_gemma":[0.001002908,0.0006541795,0.001120763,0.0004318906,0.0007504059,0.0006839559,0.0003681075,0.002526911,0.0006157379],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001019325,"about_ca_system_score_gemma":0.003114566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009408048,"about_ca_topic_score_gemma":0.003437311,"domain_scores_codex":[0.9992518,0.0003504943,0.00004151335,0.0001268886,0.0001236668,0.000105733],"domain_scores_gemma":[0.9990098,0.0001654885,0.0001846528,0.0000730629,0.00007611016,0.0004907656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6126884,0.1406383,0.01701588,0.00139268,0.003156274,0.0006531583,0.0005673304,0.004302664,0.1018925,0.0003052616,0.003611312,0.1137764],"study_design_scores_gemma":[0.4370322,0.5372954,0.01433702,0.00002228179,0.0006435884,0.0005292744,0.0000420903,0.001152298,0.005306742,0.000107875,0.003503781,0.0000275484],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953631,0.001639112,0.000354094,0.0002490562,0.00005730811,0.001533215,0.0002974148,0.00003060989,0.0004760116],"genre_scores_gemma":[0.9913471,0.001599071,0.002120001,0.0004769155,0.0001529921,0.001789385,0.001195137,0.00001943774,0.001299864],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002869057,"threshold_uncertainty_score":0.01284707,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08551078911157818,"score_gpt":0.3209049142133281,"score_spread":0.2353941251017499,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}